Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.
PMID 41842971 · PMC13132380 · The Journal of clinical investigation · 2026 · 8 claims · 8 setups
PRC2i/EZH2i alone or combined with AR inhibitors induce diverse cell state programs (CSPs) that increase tumor cell invasion, metastasis, and drug resistance despite only modest suppression of tumor growth.
-
Full-text index only
Critical evaluation of drug response prediction models with DrEval.
PMID 42120410 · PMC13168506 · Nature communications · 2026 · 8 claims · 6 setups
DrEval is a living open-source benchmarking pipeline for unbiased, biologically meaningful evaluation of cancer drug response prediction models, integrating standardized preprocessing, hyperparameter tuning, statistically rigorous evaluation, cross-study benchmarks, and ablation studies.
-
Full-text index only
Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.
PMID 41815287 · PMC12971725 · Blood neoplasia · 2026 · 8 claims · 8 setups
EIF4A1 is highly expressed in AML stem- and progenitor-like cells relative to healthy hematopoietic stem/progenitor cells
-
Full-text index only
SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.
PMID 41807550 · PMC13249849 · NPJ precision oncology · 2026 · 8 claims · 8 setups
MCL1 inhibition is synthetic lethal with SMARCA4/2 loss in SCCOHT and NSCLC cells
-
Has reproduction · 73
RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia.
PMID 39820365 · PMC11739599 · Nature communications · 2025 · 8 claims · 8 setups
RSK1 is a conserved, exploitable therapeutic dependency across MPN and secondary AML
-
Full-text index only
Single-cell resolution of an open chromatin signature in persister tumor cells.
PMID 41485222 · PMC12978573 · Cell reports · 2026 · 8 claims · 8 setups
Single-nucleus multi-omic (snRNA-seq + snATAC-seq) profiling of fallopian tube, treatment-naive, and NACT-treated HGSOC tissue identifies a persister cell signature (PCS) defining the chemotherapy-tolerant state.